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Results. Mean (median) baseline urine protein excretion wasProteinuria as a modifiable risk factor for the progression of
1.8 (0.94) g/day. Patients with higher baseline urine proteinnon-diabetic renal disease.
excretion values had a greater reduction in proteinuria duringBackground. Angiotensin-converting enzyme (ACE) inhib-
the follow-up in association with treatment with ACE inhibi-itors reduce urine protein excretion and slow the progression of
tors and in association with lowering systolic and diastolic bloodrenal disease. The beneficial effect in slowing the progression
pressures (interaction P 0.001 for all). A higher level of urineof renal disease is greater in patients with higher urine protein
protein excretion during follow-up (baseline minus change) wasexcretion at the onset of treatment. We hypothesized that the
associated with a greater risk of progression [relative risk 5.56greater beneficial effect of ACE inhibitors on the progression
(3.87 to 7.98) for each 1.0 g/day higher protein excretion]. Afterof renal disease in patients with higher baseline levels of protein-
controlling for the current level of urine protein excretion,uria is due to their greater antiproteinuric effect in these patients.
Methods. Data were analyzed from 1860 patients enrolled the beneficial effect of ACE inhibitors remained significant
in 11 randomized controlled trials comparing the effect of anti- [relative risk for ACE inhibitors vs. control was 0.66 (0.52 to
hypertensive regimens, including ACE inhibitors to regimens 0.83)], but there was no significant interaction between the
not including ACE inhibitors on the progression of non-dia- beneficial effect of ACE inhibitors and the baseline level of
betic renal disease. Multivariable linear regression analysis was urine protein excretion.
used to assess the relationship between the level of proteinuria Conclusions. The antiproteinuric effects of ACE inhibitors
at baseline and changes in urine protein excretion during fol- and lowering blood pressure are greater in patients with a
low-up. The Cox proportional hazards analysis was used to higher baseline urine protein excretion. The greater beneficial
assess the relationship between changes in urine protein excre- effect of ACE inhibitors on renal disease progression in pa-
tion during follow-up and the effect of ACE inhibitors on the tients with higher baseline proteinuria can be explained by
time to doubling of baseline serum creatinine values or onset their greater antiproteinuric effects in these patients. The cur-
of end-stage renal disease. rent level of urine protein excretion is a modifiable risk factor
for the progression of non-diabetic renal disease. ACE inhibi-
tors provide greater beneficial effect at all levels of current
1 Other members of the Angiotensin-Converting Enzyme Inhibition urine protein excretion.
and Progression of Renal Disease (AIPRD) Study Group include: R.
Toto (Dallas, TX, USA), B.M. Brenner (Boston, MA, USA), A. Kamper
(Copenhagen, Denmark), P. Zucchelli (Malpighi-Bologna, Italy), G.
Becker (Melbourne, Australia), A. Himmelmann (Goteborg, Sweden), The level of blood pressure has long been recognized
K. Bannister (Adelaide, Australia), P. Landais (Paris, France), A. Perna
as a modifiable risk factor for the progression of renal(Bergamo, Italy), S. Strandgaard (Copenhagen, Denmark), B.U. Ihle
(Melbourne, Australia), L. Hannson (Goteborg, Sweden), J.P. Gru¨nfeld disease. Recently, it has been shown that proteinuria
(Paris, France), G.G. Van Essen (Groningen, The Netherlands), A.J. is also an independent predictor of progression of renal
Apperloo (Groningen, The Netherlands), L. Oldrizzi (Verona, Italy),
disease. A higher level of urine protein at the onset ofN.E. Madias (Boston, MA, USA), B. Delano (Brooklyn, NY, USA),
T. Karim (Boston, MA, USA), and M. Reddy (Boston, MA, USA). therapy is associated with a faster rate of progression,
and a reduction in proteinuria during treatment is associ-Key words: ACE inhibitors, antihypertensive therapy, urine protein,
ated with slowing progression [1–7]. Lowering blood pres-blood pressure, management of renal disease, angiotensin-converting
enzyme, kidney failure. sure is associated with reducing urine protein excretion,
and angiotensin-converting enzyme (ACE) inhibitors areReceived for publication January 4, 2001
more effective than other antihypertensive agents in low-and in revised form April 9, 2001
Accepted for publication April 16, 2001 ering urine protein excretion and in slowing the progres-
sion of renal disease [8–14]. The Modification of Diet in 2001 by the International Society of Nephrology
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Renal Disease (MDRD) Study showed that the benefi- the similarity of study designs and patient characteristics
(Table 1), and has been discussed previously [7, 13].cial effect of strict blood pressure control on the progres-
sion of non-diabetic renal disease was greater in patients Justification for pooling placebo-controlled and active-
drug controlled trials is based on the presence of pre-with higher urine protein excretion at the onset of therapy
[5]. We recently reported that the beneficial effect of existing hypertension and the use of antihypertensive
agents in the vast majority of patients in the control groupsACE inhibitors on the progression of non-diabetic renal
disease also was greater in patients with higher urine in each clinical trial. Thus, the comparison of randomized
groups in the pooled analysis addresses the clinicallyprotein excretion at baseline [7]. Thus, the baseline level
of urine protein excretion not only predicts the risk of relevant question of whether antihypertensive regimens
containing ACE inhibitors are more effective in slowingprogression of renal disease, but it also modifies the
response to treatment with antihypertensive agents. the progression of non-diabetic renal disease than anti-
hypertensive regimens not including ACE inhibitors.This analysis sought to explore the following two ques-
tions. First, what is the relationship between baseline A total of 1946 patients were randomly assigned to
antihypertensive regimens containing ACE inhibitors orproteinuria and changes in proteinuria during antihyper-
tensive therapy? We hypothesized that patients with those without ACE inhibitors: 983 in the ACE inhibitor
group and 963 in the control group. Sixty-six patientshigher levels of proteinuria at baseline would have a
greater reduction in proteinuria in association with treat- were excluded because of non–insulin-dependent diabe-
tes, and 20 patients were excluded because of missingment with ACE inhibitors and with lowering systolic and
diastolic blood pressures. Second, what is the relation- baseline values for either blood pressure, serum creati-
nine, or urine protein excretion. Thus, the final studyship among baseline proteinuria, changes in proteinuria,
and the beneficial effect of ACE inhibitors on the pro- population for this analysis included 1860 patients: 941
in the ACE inhibitor group and 919 in the control group.gression of renal disease? We hypothesized that after
controlling for the change in proteinuria during follow- Data were available for 22,613 visits. No baseline vari-
ables differed significantly between the 1860 patientsup, there would be no relationship between the baseline
level of proteinuria and the beneficial effect of ACE included in the analysis and the 20 patients excluded
because of missing values.inhibitors on progression. If both these hypotheses are
correct, then the greater beneficial effect of ACE inhibi- Target blood pressure was 140/90 mm Hg or less in
all studies. All patients were followed at a frequency oftors in patients with higher baseline urine protein excre-
tion values is due to their greater antiproteinuric effect at least once every three months for the first year and
at least once every six months thereafter. Blood pressurein patients with greater baseline proteinuria.
This conclusion would simplify the approach to man- assessment and laboratory parameters were repeated at
each visit.agement of non-diabetic renal disease. The current level
of proteinuria, rather than the baseline level, could be Supine systolic and diastolic blood pressure were mea-
sured after a five- to ten-minute rest in all studies, exceptused to assess the risk of progression and to guide thera-
peutic interventions. Interventions to reduce proteinuria one, which provided only sitting blood pressure readings
[16]. Laboratory methods for measurement of urine pro-in non-diabetic renal disease could target the current level
of urine protein excretion, just as the current level of tein varied across studies. Two of eleven studies per-
formed a dipstick assessment for urine protein and per-blood pressure is the target of antihypertensive therapy.
formed quantitative measurement only if the dipstick
was positive [17, 20]. For these two studies, all values of
METHODS
“dipstick negative” were assigned a value of 0.1 g/day.
Studies The remaining nine studies performed a quantitative
measurement of urine protein for all patients. In all stud-Individual patient data were analyzed from random-
ized controlled trials testing the efficacy of ACE inhibi- ies, results for urine protein excretion equal to or less
than 0.1 g/day were also assigned a value of 0.1 g/day.tors in non-diabetic renal disease (personal communica-
tions, B.M. Brenner and R. Toto) [12, 14–22]. Criteria Values of greater than 0.1 g/day were recorded as the
exact values reported in the study.for inclusion of clinical trials in the individual patient
data meta-analysis, search strategies for identification of
Outcomesclinical trials, and details of database formulation have
been described previously [13]. Enalapril was used in Two primary outcomes were selected for our current
analyses. First, a change in urine protein excretion duringseven studies (personal communications, B.M. Brenner
and R. Toto) [16–19, 21]. Captopril [15], benazepril [12], follow-up was defined as the baseline level minus the
level during follow-up. For descriptive analyses, the levelcilazapril [20], and ramipril [14, 22] were used in one
study each. during follow-up was defined as the mean of all values
recorded during follow-up. Repeated-measures analysisJustification for pooling the 11 clinical trials is based on
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Table 1. Study and patient characteristics in the randomized controlled trials included in the pooled analysis
Study numbera 1 2 3 4 5 6 7 8 9 10 11
Reference [15] [16] PC PC [17] [18] [19] [20] [21] [12] [14, 22]
Study characteristics
Sample size 121 55 106 122 103 99 47 255 67 562 323
Planned duration of follow-up years 3 2 3 3 4 3 1 2 2 3 2.2
Study medicine in ACE-inhibitor groupb C E E E E E E CL E B R
Dose range of ACE inhibitor mg/day 12.5–50 2.5 5–40 5–40 10–40 5–10 5–20 2.5–5 5 10 1.25–5
Study medicine in control groupc S [n] N P P S [a] S [a] S [n] S [a] P P P
Concomitant anti-hypertensive medications
in both groupsa DF BCDG BDEF BDEFG CD CDF BDE BCD BCDEF BCDEFG BCDEFG
Blinding No No Yes Yes Yes No Yes No Yes Yes Yes
Dietary advice Yes Yes Yes Yes Yes No Yes No Yes Yes Yes
Patient Characteristicsd
Men % 63 49 65 64 65 50 79 49 48 72 77
White % 100 100 44 40 99 100 100 100 100 100 99
Cause of renal disease %
Glomerular disease 26 31 33 7 26 50 100 0 60 34 51
Hypertensive nephrosclerosis 29 0 36 90 29 7 0 100 0 17 13
Tubulointerstitial disease 20 29 5 3 22 19 0 0 2 19 7
Polycystic kidney disease 10 20 14 0 14 15 0 0 15 11 1
Other 15 20 12 0 9 9 0 0 23 19 28
Hypertensione % 100 93 98 100 100 100 100 100 100 92 84
Age years 55 50 47 52 51 51 48 63 46 51 49
Baseline serum creatinine mg/dL 3.0 5.0 2.7 2.6 1.8 3.0 1.4 1.0 4.2 2.1 2.2
Baseline SBP mm Hg 165 147 141 130 154 167 153 161 150 142 144
Baseline DBP mm Hg 100 90 91 82 91 102 95 94 88 88 89
Baseline urine protein g/day 1.7 1.9 2.3 0.7 1.6 2.2 1.7 0.1 2.1 1.8 3.4
Decline in SBP mm Hg 24 11 10 3 16 13 18 4 7 2 4
Decline in DBP mm Hg 13 6 8 1 11 11 10 4 2 2 2
Decline in urine protein g/day 0.1 0.5 0.8 0.2 0.4 0.4 0.1 0 0.2 0.2 0.3
Abbreviations are: ACE, angiotensin-converting enzyme; PC, personal communication; SBP, systolic blood pressure, DBP, diastolic blood pressure.
a Concomitant antihypertensive medications in both groups: B, beta-adrenergic blockers; C, calcium channel blockers; D, diuretics: E, peripheral alpha-adrenergic
blockers; F, central alpha-adrenergic agonists; G, vasodilators
b Study medication in ACE inhibitor group: C, captopril; E, enalapril; CL, cilazapril; B, benazepril; R, ramipril
c Study medication in control group: S, specified; N, not specified; P, placebo; [n], nifedipine; [a], atenolol/acebutalol
d Values indicate percentages or means, as appropriate
e Hypertension was defined as either 1) SBP  140 mm Hg, 2) DBP  90 mm Hg, 3) taking antihypertensive medications prior to enrollment, or 4) classified as
“hypertensive” by the clinical investigators
was not used to assess changes during follow-up because (2) Urine protein excretion 0.5 to 2.9 g/day. This cate-
the times of follow-up measurements varied across stud- gory includes patients with “non–nephrotic-range pro-
ies. For multivariable models, measurements at each fol- teinuria,” which may be due to a wide variety of renal
low-up time were assessed. Second, progression of renal diseases.
disease was defined as the combined endpoint of a dou- (3) Urine protein excretion 3.0 to 6.0 g/day. Urine pro-
bling of baseline serum creatinine or onset of end-stage tein excretion greater than 3.0 g/day is generally consid-
renal disease (ESRD). ESRD was defined as the onset ered “nephrotic-range proteinuria.” Most, but not all,
of chronic dialysis therapy. patients with this level of proteinuria have an underlying
glomerular disease with clinical features of the nephroticStatistical analyses
syndrome.
SAS (SAS Institute Inc., Cary, NC, USA) and S Plus (4) Urine protein excretion 6.0 g/day. Patients with
(Stat Sci, a division of MathSoft Inc., Seattle WA, USA) these high levels of proteinuria make up a small fraction
were used for statistical analyses. For descriptive pur-
of patients with chronic renal disease and may have clini-poses, we compared the patients’ baseline characteristics
cal complications from hemodynamic and metabolicand outcomes during follow-up in subgroups of patients
complications of nephrotic syndrome. For this reason,defined by their baseline urine protein excretion. The
this subgroup was considered separately from other pa-following four subgroups were defined a priori:
tients with nephrotic-range proteinuria. Only eight stud-(1) Urine protein excretion 0.5 g/day. This cut point
ies included patients with baseline proteinuria this high.is just above the normal range in most clinical labora-
Baseline characteristics and outcomes were comparedtories for urine protein excretion. Thus, patients in this
among these subgroups using analysis of variance or chi-category have normal or minimally elevated urine total
square tests as appropriate.protein excretion and would include most patients desig-
nated as having “microalbuminuria.” For all other analyses, urine protein excretion on a
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continuous scale was used; multivariable linear-regression the difference between the log of the predicted values
analysis was used to assess factors associated with and the linear predictor from the Cox model. We added
changes in urine protein excretion at each follow-up visit 0.01 to those values predicted to equal zero in order to
during which urine protein excretion was measured. The be able to calculate the log.
variables of interest were treatment assignment (ACE
inhibitor group vs. control group), change in systolic
RESULTSblood pressure, change in diastolic blood pressure, base-
line urine protein, and terms for interactions of each Studies and patients
variable with baseline urine protein excretion. Potential Characteristics of studies and patients are given in
covariates included baseline urine protein excretion, Table 1. Mean baseline urine protein excretion varied
gender, race, natural logarithm of age, reciprocal of base- from 0.1 to 3.4 g/day across the studies. Table 2 shows
line serum creatinine, baseline systolic and diastolic patient characteristics for the entire study group and for
blood pressures, treatment assignment (randomization subgroups stratified by baseline urine protein excretion
to the ACE-inhibitor group vs. the control group),
values. Sixty-five percent of the patients were male, andchanges in systolic and diastolic blood pressures during
94% were non-black. Causes of renal disease includedfollow-up, study variables, and terms for interactions of
glomerular disease (33%), hypertensive nephrosclerosiseach covariate with baseline proteinuria. For consistency
(33%), tubulointerstitial disease (12%), polycystic kid-with our previous report (which could not include a term
ney disease (8%), and other (15%). Mean age was 52for each study), terms were included for studies 2, 5, 10,
years. Mean serum creatinine was 2.3 mg/dL, and meanand 11 [7]. The cause of renal disease was not included
systolic and diastolic blood pressures were 148 and 91as a covariate because it was not ascertained uniformly
mm Hg, respectively. The mean (SD) urine protein ex-in different studies and because it is usually assigned
cretion was 1.8 (2.3) g/day, while the median (inter-based, in large part, on urine protein excretion rate.
quartile range) urine protein excretion was 0.90 (0.18 toThe Cox proportional hazards regression analysis was
2.3) g/day.used to assess the factors associated with the combined
Baseline characteristics of patients varied accordingendpoints of doubling of baseline serum creatinine or
to baseline urine proteinuria. As shown, patients withonset of ESRD. The time associated with the endpoint
higher baseline urine protein were younger, more likelyachieved first was used. Variables of interest for these
to be men, had a greater prevalence of glomerular dis-analyses were baseline urine protein excretion and treat-
ment assignment (ACE inhibitor group vs. control group) ease, and higher baseline serum creatinine values (P 
as fixed variables and change in urine protein excretion 0.001 for all). Systolic and diastolic blood pressures did
as a time-dependent variable. As in previous analyses not differ among subgroups.
[7], we adjusted for the natural logarithm of age, gender, Mean (SD) decline in urine protein from baseline to
reciprocal of baseline serum creatinine, baseline systolic follow-up was 0.20 (1.46) g/day: 0.43 (1.67) g/day in the
blood pressure, and terms for studies 2, 5, 10, and 11 as ACE-inhibitor group versus 0.03 (1.16) g/day in the
fixed covariates. An adjustment for changes in systolic control group (P 0.001). Higher baseline urine protein
blood pressure during follow-up also was made as a time- excretion was associated with a significantly greater de-
dependent covariate. The interaction term for the treat- cline in proteinuria during follow-up in both the ACE
ment effect and baseline urine protein excretion was inhibitor and control groups (P 0.001 for both). Table 2
tested in the model with and without the inclusion of and Figure 1 show the pattern of change in urine protein
change in urine protein excretion. Analyses were re- during follow-up. In both the ACE inhibitor and control
peated after substituting the current level of urine pro-
groups, mean urine protein excretion declined in patients
tein excretion for baseline and change in urine protein
with higher baseline proteinuria and rose in patients withexcretion. The proportional hazards assumption was
lower baseline proteinuria.checked by computing the Schoenfeld residuals and de-
As described previously [7] and shown in Table 2,termining that they exhibited no significant correlation
176 patients developed ESRD (70 in the ACE inhibitorwith the ranked failure times [23–25]. A graphical check
group vs. 106 in the control group, P  0.02), and 311was also made by plotting the residuals against time
patients developed the combined endpoint of a doublingand fitting a smooth curve with 95% confidence bands.
of serum creatinine or onset of ESRD (124 in the ACEPotential influence points were checked by examining
inhibitor group vs. 187 in the control group, P  0.001).the score residuals. Linearity of covariates was assessed
Patients with higher baseline proteinuria had a higherby modeling the binary outcome in a Poisson generalized
risk of both outcomes (P  0.001 for both). These rela-additive regression as a function of all the terms in the
tionships were observed in both the ACE inhibitor andsurvival model using a smooth spline representation of
the continuous variables, and an offset term that equaled in the control groups (P  0.001 for all).
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Table 2. Comparison of baseline characteristics and outcomes in subgroups defined by baseline urine protein excretion
Urine protein excretion g/day
Total 0.5 0.5–3.0 3.0–6.0 6.0 P valueb
Number of patients 1860 730 728 301 101
Urine protein excretion g/day 1.8 (2.3) 0.15 (0.1) 1.5 (0.7) 4.2 (0.8) 8.7 (3.1)
Baseline characteristics
Men 1215 (65) 412 (56) 481 (67) 234 (78) 84 (83) 0.001
Non-black race 1746 (94) 655 (90) 700 (96) 293 (97) 98 (97) 0.001
Cause of renal disease 0.001
Glomerular disease 611 (33) 73 (10) 302 (41) 169 (56) 67 (66)
Polycystic kidney disease 142 (8) 81 (11) 49 (7) 9 (3) 3 (3)
Hypertensive nephrosclerosis 614 (33) 434 (59) 146 (20) 28 (9) 6 (6)
Tubulointerstitial disease 219 (12) 84 (12) 105 (14) 28 (9) 2 (2)
Other 274 (15) 58 (8) 126 (17) 67 (22) 23 (23)
Age years 51.9 (12.9) 56.9 (10.6) 49.4 (12.9) 47.6 (13.4) 47.2 (14.8) 0.001
Serum creatinine mg/dl 2.3 (1.2) 1.8 (1.0) 2.6 (1.3) 2.6 (1.0) 2.9 (1.3) 0.001
Systolic blood pressure mm Hg 148 (21.5) 149 (22.4) 147 (21) 150 (20.8) 150 (21.9) 0.23
Diastolic blood pressure mm Hg 91 (10.9) 90 (10.3) 91 (11.4) 91 (10.9) 90 (10.2) 0.04
Outcomes
Decline in urine protein excretion g/day 0.20 (1.46) 0.15 (0.49) 0.06 (0.95) 0.83 (1.63) 2.89 (3.75) 0.001
ACE inhibitor group 0.43 (1.67) 0.10 (0.39) 0.14 (0.92) 1.18 (1.64) 3.93 (4.22) 0.001
Control group 0.03 (1.16) 0.20 (0.58) 0.26 (0.95) 0.48 (1.55) 1.57 (2.54) 0.001
ESRD 176 (9.5) 22 (3.0) 91 (12.5) 44 (14.6) 19 (18.8) 0.001
ACE inhibitor group 70 (7.4) 11 (2.9) 35 (9.6) 16 (11.4) 8 (14.6) 0.001
Control group 106 (11.6) 11 (3.1) 56 (15.6) 28 (18.3) 11 (23.9) 0.001
Doubling of serum creatinine or ESRD 311 (16.7) 51 (7.0) 146 (20.1) 81 (26.9) 33 (32.7) 0.001
ACE inhibitor group 124 (13.2) 29 (7.7) 54 (14.8) 27 (19.2) 14 (25.5) 0.001
Control group 187 (20.5) 22 (6.2) 92 (25.7) 54 (35.3) 19 (41.3) 0.001
Results are given as N (%) or mean (SD) as appropriate.
a Ranges include left end point, but not right end point
b P values are for comparisons across subgroups defined by urine protein excretion
Factors associated with changes in proteinuria a greater antiproteinuric effect of ACE inhibitors and
of lowering systolic and diastolic blood pressures.We next considered the relationship of baseline urine
These analyses were repeated after transforming base-protein excretion, ACE inhibitor therapy, and changes
line and follow-up urine protein excretion to the logarith-in systolic and diastolic blood pressure with changes in
mic scale. In this model, the decline in urine proteinproteinuria during follow-up. Without controlling for
excretion during follow-up was independently associatedother factors, higher baseline urine protein excretion was
with the use of ACE inhibitors versus control and withassociated with greater reduction in proteinuria during
the decline in systolic and diastolic blood pressures.follow-up. A 1.0 g/day higher baseline urine protein ex-
However, the interactions of each factor with baselinecretion was associated with a 0.39 (0.38 to 0.40) g/day
urine protein excretion were no longer significant. Thesegreater reduction in proteinuria during follow-up.
findings are consistent with the interpretation that ACEAfter controlling for significant baseline covariates, in
inhibitors and lowering systolic and diastolic blood pres-those treated with ACE inhibitors, a greater decline in
sures are each associated with a constant fractional re-systolic blood pressure and greater decline in diastolic
duction in proteinuria, irrespective of the baseline levelblood pressure were each associated with a greater re-
of proteinuria. The percent reductions (and 95% confi-duction in proteinuria (P  0.001, P  0.001, and P 
dence intervals) for these three factors were 21 (19 to0.10, respectively). Separate multivariable models were
23), 7 (6 to 8), and 4 (3 to 5), respectively.used to test the interaction of each factor with baseline
urine protein excretion. All three interaction terms were
Relationship of proteinuria to progressionsignificant (interaction P  0.001 for all). As shown in
of renal diseaseFigure 2A, there was a significantly greater decline in
Next, we explored the relationship of urine proteinurine protein excretion with ACE inhibitors at higher
excretion at baseline and changes during follow-up tolevels of baseline urine protein excretion. A greater de-
the effect of ACE inhibitors on the progression of renalcline in urine protein excretion, albeit of much lesser
disease, as assessed from the combined outcome of dou-magnitude, with changes in systolic and diastolic blood
bling of baseline serum creatinine or onset of ESRD.pressures (Fig. 2 B, C, respectively), also was observed at
As reported previously, the unadjusted relative risk forhigher levels of baseline urine protein. Therefore, patients
with higher baseline urine protein excretion experienced the combined outcome in the ACE-inhibitor group ver-
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Fig. 1. Comparison between randomized
groups of urine protein excretion during fol-
low-up for each subgroup. Subgroups are de-
fined in Table 2. (A) Subgroup with baseline
urine protein6.0 g/day (N 101, mean base-
line urine protein  8.7 g/day). (B) Subgroup
with baseline urine protein 3.0 to 6.0 g/day (N
301, mean baseline urine protein 4.2 g/day).
(C) Subgroup with baseline urine protein 0.5
to 3.0 g/day (N  728, mean baseline urine
protein 1.5 g/day). (D) Subgroup with base-
line urine protein 0.5 g/day (N  730, mean
baseline urine protein  0.15 g/day). (Note
that ranges include the left end point but not
the right end point.) Vertical axis depicts mean
values for urine protein at baseline and vari-
ous times after randomization for patients ran-
domized to the ACE inhibitor group versus
the control group. Horizontal axis depicts
months after randomization. Follow-up mea-
surements were reported more often during
the first two years and less often thereafter.
Not all patients had follow-up measurements
of urine protein excretion at each visit. For
statistical analyses, mean urine protein excre-
tion during follow-up was defined as the mean
of all available follow-up values for each pa-
tient. Change during follow-up () was de-
fined as the baseline value minus the mean
follow-up value for each patient. P values are
for the comparison of change in urine protein
excretion during follow-up between the ACE
inhibitor group versus control group. Symbols
are: () control; () ACE inhibitor.
sus the control group was 0.64 (0.51 to 0.80) [7]. For risk of 2.94 (2.05 to 4.22) per 1.0 g/day]. The beneficial
effect of ACE inhibitors remained significant [relativethese analyses, three different multivariable models were
used: (1) controlling for baseline urine protein excretion, risk of 0.59 (0.46 to 0.74)]. In addition, there was a sig-
nificant interaction between baseline urine protein excre-(2) controlling for the baseline level and changes in urine
protein excretion during follow-up, (3) and controlling tion and the treatment effect (interaction P  0.001),
with a greater benefit of ACE inhibitors (lower relativefor the baseline level and the current level of proteinuria
during follow-up. Each model also controlled for signifi- risk) in patients with higher baseline urine protein excre-
tion (Fig. 3A).cant baseline factors.
In the first model, as reported previously [7], higher In the second model, also as reported previously [7],
a greater decline in urine protein excretion during fol-baseline urine protein excretion was a significant inde-
pendent risk factor for the combined outcome [relative low-up was associated with a lower risk of the combined
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outcome [relative risk of 0.20 (0.13 to 0.32) per 1.0
g/day]. In this model, the effect of baseline urine protein
remained significant [relative risk of 6.18 (4.00 to 9.54)
per 1.0 g/day], as did the beneficial effect of ACE inhibi-
tors [relative risk of 0.70 (0.55 to 0.88)]. However, the
interaction between the treatment effect and baseline
proteinuria was no longer significant (P 0.26; Fig. 3B).
These results suggest three important conclusions. First,
as reported before, the beneficial effect of ACE inhibi-
tors is mediated by factors in addition to the antiprotein-
uric effect of ACE inhibitors [7]. Second, the greater
beneficial effect of ACE inhibitors in patients with higher
baseline urine protein excretion is due to the greater
antiproteinuric effect of ACE inhibitors in these patients.
Third, the current level of urine protein excretion during
follow-up (the baseline level minus the change from
baseline) is a better predictor of the risk of progression
than the baseline level alone.
In the third model, these analyses were repeated sub-
stituting the current level of urine protein excretion dur-
ing follow-up for the baseline urine protein excretion
and change in urine protein excretion. Higher current
urine protein excretion was an independent risk factor
for the combined outcome [relative risk of 5.56 (3.87 to
7.98) for each 1.0 g/day]. After controlling for the current
level of urine protein excretion, the beneficial effect of
ACE inhibitors persisted [relative risk 0.71 (0.56 to
0.89)]. In this model, the interaction between the treat-
ment effect and current urine protein excretion was not
significant (P  0.93; Fig. 3C). This indicates that ACE
inhibitors are more effective than other antihypertensive
agents in slowing progression at all levels of current urine
protein excretion. The goodness of fit for this model was
as high as the model including the baseline level of urine
protein excretion and the change in follow-up, suggesting
that the current level of urine protein excretion predicts
the risk of progression as well as the baseline level plus
the change during follow-up.
Fig. 2. Relationship of baseline urine protein excretion to changes in DISCUSSION
urine protein excretion during follow-up. Vertical axis indicates the de-
cline in urine protein excretion from baseline to follow-up associated with Hypertension and proteinuria are risk factors for the
treatment with ACE inhibitors versus control antihypertensive agents progression of chronic renal disease. We previously showed
(A), lowering systolic blood pressure (SBP) by 10 mm Hg (B), and lowering
that regimens including ACE inhibitors were more effec-diastolic blood pressure (DBP) by 10 mm Hg (C). Horizontal axis indicates
baseline urine protein excretion. Diagonal lines indicate regression coeffi- tive than other antihypertensive regimens in lowering
cient and 95% confidence interval for the relationship between baseline blood pressure, lowering urine protein excretion, and
urine protein and decline in urine protein excretion for each interven-
slowing the progression of renal disease in patients withtion (interaction terms). Patients with higher baseline urine protein
excretion have a significantly greater decline in urine protein excretion non-diabetic renal disease [7]. The beneficial effect of
in association with each intervention. Results are derived from a multi- ACE inhibitors on progression was greater in patientsvariable linear regression model for the decline from baseline in urine
protein excretion at each follow-up visit, controlling for gender (refer-
encemale), natural logarithm of age (reference 55 years), baseline
urine protein excretion, reciprocal of serum creatinine (reference serum
creatinine  2.0 mg/dL), interaction between urine protein excretion
and reciprocal of serum creatinine, SBP (reference  150 mm Hg), control), decline in SBP (reference 0 mm Hg), decline in DBP (refer-
DBP (reference  90 mm Hg), treatment assignment (treatment with ence 0 mm Hg), and study terms. Interactions were tested in separate
ACE inhibitors vs. control antihypertensive agents, reference  models. P  0.001 in all three panels.
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with higher urine protein excretion at the onset of treat-
ment. Declines in blood pressure and urine protein dur-
ing treatment were independently associated with a
lower risk of progression; however, after controlling for
these factors, the benefit of ACE inhibitors on progres-
sion remained significant. We concluded that the benefit
of ACE inhibitors on progression of renal disease was
not mediated solely by their antihypertensive and anti-
proteinuric effects. Thus, the greater beneficial effect of
ACE inhibitors in patients with higher baseline protein-
uria was unexplained. No other baseline factors modified
the beneficial effect of ACE inhibitors on progression.
Our current study shows that antihypertensive regi-
mens containing ACE inhibitors have a greater benefi-
cial effect on lowering urine protein excretion than anti-
hypertensive regimens not containing ACE inhibitors,
and that the beneficial effect is greater in patients with
higher baseline proteinuria (Figs. 1 and 2 and Table 2).
Furthermore, after controlling for changes in proteinuria
during follow-up, the beneficial effect of ACE inhibitors
on progression is no longer related to the level of protein-
uria at baseline (Fig. 3). We conclude that the greater
beneficial effect of ACE inhibitors on progression in pa-
tients with higher baseline urine protein excretion reflects
their greater antiproteinuric effect in these patients. While
patients with higher urine protein excretion at baseline
benefit more from ACE inhibition than patients with
lower urine protein excretion, the level of proteinuria
after treatment is begun is a better predictor of the risk
of progression than the level at baseline. A lower level
of urine protein excretion during follow-up predicts a
lower risk. At all levels of urine protein during follow-up,
the risk is lower in patients treated with ACE inhibitors.
Overall, these results simplify the approach to the
management of non-diabetic renal disease. Lowering blood
pressure, lowering urine protein excretion, and ACE
inhibition are independent therapeutic goals in the treat-
ment of non-diabetic renal disease. In addition, we show
that the current level of proteinuria, rather than the
level at the onset of treatment, should be the target of
Fig. 3. Relationship of urine protein excretion to the effect of ACE
antiproteinuric therapy. To our knowledge, this is theinhibitors on doubling of baseline serum creatinine or ESRD. Vertical
axis in all figures is the relative risk of the combined outcome of doubling first demonstration of this principle in a large, generaliz-
of serum creatinine or ESRD in the ACE inhibitor group compared able study using rigorous statistical methods.
with the control group (treatment effect). Horizontal axis is either
the baseline level or current level during follow-up of urine protein
excretion. Solid and dotted lines indicate point estimates and 95%
confidence intervals for the relative risks, respectively. (A) The relation-
ship of the treatment effect to baseline urine protein in the multivariable
The beneficial effect of ACE inhibitors remains significant, but does notmodel controlling only for significant baseline patient and study charac-
vary with current urine protein excretion (interaction P  0.93). Resultsteristics (modified from Figure 2) [7]. The beneficial effect of ACE
are from a multivariable proportional hazards model examining the effectinhibitors is greater (lower relative risk) at higher levels of baseline
of treatment assignment (ACE inhibitors vs. control antihypertensiveurine protein excretion. The test for interaction between baseline urine
agents) on time to doubling of baseline serum creatinine or onset ofprotein excretion and treatment was significant (P  0.001). (B) The
ESRD, controlling for baseline factors and follow-up factors. Baselinetreatment effect after controlling for the change in urine protein excre-
factors in the multivariable model include gender, logarithm of age,tion in addition to the baseline and study characteristics. The beneficial
reciprocal of serum creatinine, systolic blood pressure, study terms, andeffect of ACE inhibitors remained significant (relative risk less than
urine protein excretion (as indicated). Follow-up factors include decline1.0), but was not related to the level of baseline urine protein excretion
in systolic blood pressure and change in urine protein excretion or follow-(interaction P  0.26). (C) The treatment effect after controlling for
up urine protein excretion (as indicated).current urine protein excretion rather than the change from baseline.
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Our database includes 11 of 14 studies and 1946 of protein excretion with other variables. However, this
would not be expected to lead to spurious associations.the 2122 (92%) patients who met the inclusion criteria
for our pooled analysis [7]. The study sample includes Second, patients were not assigned at random to differ-
ent targets for urine protein excretion during follow-22,613 visits in 1860 patients. This represents the largest
set of data collected prospectively in patients with non- up. Thus, the association between higher urine protein
excretion during follow-up and higher risk of progressiondiabetic renal disease with longitudinal data on ACE
inhibitor therapy, blood pressure, and urine protein ex- may be confounded by other unmeasured variables or
reflect reverse causation. However, the association de-cretion and outcomes of renal disease for the comparison
of ACE inhibitors to other antihypertensive agents. The tected was robust [relative risk of 5.56 (3.87 to 7.98) for
each 1.0 gld, P  0.001], even after controlling for otherdistribution of renal diagnosis is roughly similar to that
observed for non-diabetic incident dialysis patients in variables, including treatment with ACE inhibitors and
baseline urine protein excretion. We suspect that higherthe United States [26]. Thus, the results should be gener-
alizable to the population of patients with non-diabetic urine protein excretion during follow-up truly is a risk
factor for progression. The definitive test of this hypothe-renal disease. Both published and unpublished data were
included, thereby minimizing publication bias, and only sis would be a randomized clinical trial, comparing two
target levels of urine protein excretion.randomized trials that followed an intention-to-treat
principle were included to minimize investigator bias. In addition, many important questions remain unan-
swered. For example, other than antihypertensive agents,Multivariable regression models were used to identify
factors associated with the level of urine protein excre- there are few therapies to reduce urine protein excretion.
Buter et al have shown that a low-salt diet or diureticstion and renal disease progression, with fixed and time-
dependent covariates to model baseline and follow-up potentiate the antiproteinuric effect of antihypertensive
agents [29]. Nonsteroidal anti-inflammatory agents thatfactors. Interaction tests rather than subgroup analyses
were used to assess “effect modification,” which limits inhibit synthesis of vasodilator prostaglandins also lower
urine protein excretion [30]. However, these drugs havethe risk of both type 1 and type 2 errors. Overall, these
methods assure the internal validity of our results. Thus, many adverse effects on renal function in patients with
chronic renal disease, including further reduction in glo-we believe our conclusions are robust.
Our analysis confirms that a higher level of urine pro- merular filtration rate and reduction in renal potassium
excretion [31]. In patients also treated with ACE inhibi-tein excretion, either at baseline or during treatment with
antihypertensive agents, is an independent risk factor for tors, nonsteroidal anti-inflammatory agents can lead to
serious hyperkalemia or acute renal failure. They arethe progression of non-diabetic renal disease. Thus, pro-
teinuria should be considered a “modifiable” risk factor. also associated with gastrointestinal side effects, which
can be serious in patients with chronic renal disease. InProteinuria may contribute to disease progression through
a number of mechanisms, including direct mesangial tox- our judgment, clinical trials are necessary before these
agents should be routinely recommended to reduce urineicity, tubular overload, toxicity from specific filtered pro-
teins, and induction of proinflammatory molecules [27, 28]. protein excretion. In addition, we have not analyzed
whether the benefit of ACE inhibitors on lowering urineOur database cannot allow inferences regarding mecha-
nisms of renal injury associated with proteinuria. protein excretion is dose dependent. These analyses are
underway. Finally, our analyses do not define the optimalThe analysis of factors associated with declining urine
protein excretion during follow-up sheds light on poten- target level for urine protein excretion during follow-up.
This determination will require analysis of the risks astial therapies to slow the progression of renal disease.
Treatment with ACE inhibitors and greater decline in well as benefits of ACE inhibitors for various levels of
urine protein excretion.systolic and diastolic blood pressure were independently
associated with a greater decline in proteinuria, as has In summary, our analyses show that a higher level
of urine protein excretion, either at baseline or duringbeen noted by others [14]. Our results show that patients
with higher baseline urine protein excretion have a follow-up, is associated with a higher risk of progression
of non-diabetic renal disease. Even after controlling forgreater reduction in urine protein excretion in response
to each of these interventions (Fig. 2), indicating a sub- their antihypertensive effects, ACE inhibitors are more
effective than other antihypertensive agents in loweringgroup of patients who are especially likely to benefit
from antihypertensive therapy with ACE inhibitors. urine protein and slowing the progression of renal dis-
ease. These beneficial effects are greater in patients withThere are a number of possible limitations of this
analysis. First, urine protein was measured according to higher urine protein excretion at baseline. The greater
beneficial effect of ACE inhibitors in slowing progres-different protocols and using different laboratory meth-
ods in the various clinical trials. In principle, this may sion in patients with higher baseline proteinuria reflects
the greater antiproteinuric effect of ACE inhibitors inintroduce measurement error in our pooled analysis,
which could weaken the observed association of urine these patients. Thus, the level of urine protein during
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